Abstract |
We evaluated the efficacy and toxicity of aclarubicin for acute non- lymphocytic leukemia ( ANLL) refractory to daunorubicin in childhood. Twenty-four patients were treated with aclarubicin and prednisolone with or without 6-mercaptopurine and behenoyl- cytosine arabinoside daily for 5 to 14 days. Of 21 evaluable patients, 14 (67%) responded: 12 obtained complete remission and 2 partial remission. The median time to reach complete remission was 37 days (range, 16 to 60 days), and the median duration of complete remission was 5.5 months (range, 2 to 41 months). The cumulative dose of anthracycline administered before the study was not considered significant for the response. The only major complication was severe bone marrow suppression; infectious episodes occurred in 14 patients (58%) and three died of sepsis and/or bleeding. The observed non-hematologic toxicities included hematuria, an elevation of serum amylase, nausea/ vomiting, and angitis. In addition, one patient showed abnormal cardiac function. Aclarubicin is therefore considered a highly active drug for remission reinduction of previously treated children suffering from ANLL with an acceptable toxicity.
|
Authors | K Nibu, F Yanai, J Okamura, Y Ikuno, H Tasaka, A Matsuzaki, H Inada, H Eguchi, R Sakai, H Koga |
Journal | Pediatric hematology and oncology
(Pediatr Hematol Oncol)
1995 May-Jun
Vol. 12
Issue 3
Pg. 251-8
ISSN: 0888-0018 [Print] England |
PMID | 7640178
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Aclarubicin
(adverse effects, therapeutic use)
- Adolescent
- Child
- Child, Preschool
- Daunorubicin
(therapeutic use)
- Drug Resistance
- Female
- Humans
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Salvage Therapy
|